.After elevating $170 thousand back in February, metabolic disease-focused BioAge Labs has submitted to debut on the public market.The Eli Lilly-partnered biotech expect to specify on the Nasdaq under the symbol “BIOA,” according to records filed along with the Securities and Exchange Compensation. The company has certainly not publicly discussed an expected financial amount for the offering.The clinical-stage company touts lead candidate azelaprag, a by mouth provided small particle slated to go into period 2 screening in combo with semaglutide– offered by Novo Nordisk under brand name Wegovy for weight reduction– in the initial fifty percent of upcoming year. Semaglutide is additionally offered as Ozempic and Rybelsus by Novo for diabetic issues.
Apelin receptor agonist azelaprag is actually developed to integrate effectively along with GLP-1 medications, increasing fat loss while keeping muscle mass. The investigational medicine was located to be well-tolerated one of 265 individuals around 8 stage 1 tests, depending on to BioAge.Recently, BioAge gathered the help of Lilly to run a test mixing azelaprag along with the Big Pharma’s GLP-1/ GIP receptor agonist tirzepatide, which is marketed for diabetic issues as Mounjaro and also Zepbound for weight loss. The companions are actually currently performing a stage 2 test of azelaprag and tirzepatide, with topline outcomes expected in the third fourth of 2025.The biotech is actually additionally considering a the hormone insulin sensitiveness proof-of-concept trial analyzing azelaprag as a monotherapy in the 1st fifty percent of following year to assist potential evidence development.
Moreover, the business intends to ask the FDA for consent in the second fifty percent of 2025 to launch human screening for an NLRP3 prevention targeting metabolic ailments and also neuroinflammation.BioAge’s anticipated move to the general public market follows a slight uptick in intended biotech IPOs from Bicara Rehabs and also Zenas Biopharma. Zooming out, the current IPO yard is actually a “combined photo,” along with top quality companies still debuting on everyone markets, only in lowered varieties, according to PitchBook.